注意缺陷多动障碍药物随机对照试验中的安慰剂与反安慰剂效应:系统综述与荟萃分析
该系统综述与荟萃分析纳入128项双盲随机安慰剂对照试验(10,578名儿童青少年和9,175名成人),评估ADHD药物的安慰剂效应与反安慰剂效应。结果显示所有疗效结局均存在显著且异质的安慰剂效应,无发表偏倚;耐受性结局存在反安慰剂效应;多数评分者的疗效结局中,安慰剂效应与药物效应呈显著正相关。
要点
- ADHD药物试验中安慰剂效应显著且异质,临床医生评分时安慰剂效应最大。
- 耐受性结局存在反安慰剂效应,且安慰剂与反安慰剂效应在不同药物间无差异。
- 多数评分者的疗效结局显示安慰剂效应与活性药物效应呈显著正相关。
核心结论
- ADHD药物随机对照试验中存在显著且异质的安慰剂效应(疗效结局)和反安慰剂效应(耐受性结局)。
- 多数评分者的疗效结局中,基线至终点的安慰剂效应与药物效应呈显著正相关,提示共享非特异性因素影响两者。
- 尽管ADHD药物优于安慰剂,临床实践中无法使用安慰剂治疗,但临床医生应尝试将与安慰剂效应相关的因素纳入临床照护。
研究设计与样本
- 系统综述与荟萃分析,检索截至2019年6月26日的已发表/未发表双盲随机安慰剂对照试验。
- 共分析128项随机对照试验,纳入10,578名儿童青少年和9,175名成人。
- 采用随机效应荟萃分析评估疗效的安慰剂效应和耐受性的反安慰剂效应,并分析研究设计与患者特征与安慰剂/反安慰剂反应的关联。
主要发现
- 所有疗效结局均存在显著且异质的安慰剂效应,无发表偏倚。
- 临床医生评分时的安慰剂效应大于其他评分者。
- 耐受性结局存在反安慰剂效应。
- 多数评分者的疗效结局中,基线至终点的安慰剂效应与基线至终点的药物效应呈显著正相关。
- 安慰剂效应和反安慰剂效应在不同药物间无差异;基线严重程度和评定量表类型影响结果。
临床怎么用
- 临床医生应尝试将与安慰剂效应相关的因素纳入ADHD患者的临床照护。
- 尽管ADHD药物优于安慰剂,但临床实践中不应使用安慰剂治疗。
局限性
- 基线严重程度和评定量表类型影响安慰剂/反安慰剂效应的评估结果。
- 未来研究应探索这些效应如何影响药物治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The nature and magnitude of placebo and nocebo responses to ADHD medications and the extent to which response to active medications and placebo are inter-correlated is unclear. To assess the magnitude of placebo and nocebo responses to ADHD and their association with active treatment response. We searched literature until June 26, 2019, for published/unpublished double-blind, randomised placebo-controlled trials (RCTs) of ADHD medication. Authors were contacted for additional data. We assessed placebo effects on efficacy and nocebo effects on tolerability using random effects meta-analysis. We assessed the association of study design and patient features with placebo/nocebo response. We analysed 128 RCTs (10,578 children/adolescents and 9175 adults) and found significant and heterogenous placebo effects for all efficacy outcomes, with no publication bias. The placebo effect was greatest for clinician compared with other raters. We found nocebo effects on tolerability outcomes. Efficacy outcomes from most raters showed significant positive correlations between the baseline to endpoint placebo effects and the baseline to endpoint drug effects. Placebo and nocebo effects did not differ among drugs. Baseline severity and type of rating scale influenced the findings. Shared non-specific factors influence response to both placebo and active medication. Although ADHD medications are superior to placebo, and placebo treatment in clinical practice is not feasible, clinicians should attempt to incorporate factors associated with placebo effects into clinical care. Future studies should explore how such effects influence response to medication treatment. Upon publication, data will be available in Mendeley Data: PROSPERO (CRD42019130292).
引用
- Faraone SV, Newcorn JH, Cipriani A, et al. Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: a systematic review and meta-analysis. Mol Psychiatry. 2021. PMID: 33972692. doi:10.1038/s41380-021-01134-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。